Earnings Releases·Nov 5, 2026, 4:31 PM ET

Cryoport — Third Quarter 2026 Earnings Summary

Total revenue reached $50.2 million in Q3 2026, a 14% year-over-year increase, while full-year 2026 revenue guidance was raised to $197–$199 million.
The company reported a net loss of $12.9 million ($0.25 per share) for Q3 2026, compared to a net loss of $8.9 million in the prior year period, though Adjusted EBITDA turned positive at $1.1 million.
Strategic growth was driven by a 20% year-over-year increase in Commercial Cell and Gene Therapy revenue and support for a record 788 global clinical trials.
Management highlighted a robust pipeline with two possible new therapy approvals and five possible BLA/MAA submissions expected in 2026, alongside strong cash reserves of $393.1 million.